Discovery of (Z)-1-(3-((1H-Pyrrol-2-yl)methylene)-2-oxoindolin-6-yl)-3-(isoxazol-3-yl)urea Derivatives as Novel and Orally Highly Effective CSF-1R Inhibitors for Potential Colorectal Cancer Immunotherapy

2021 ◽  
Author(s):  
Qi Lv ◽  
Xiang Pan ◽  
Dan Wang ◽  
Quanjin Rong ◽  
Ben Ma ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Immunotherapy ◽  
Urea Derivatives ◽  
Highly Effective

scholarly journals 5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer

2001 ◽  
Vol 84 (8) ◽  
pp. 1023-1028 ◽  
Author(s):  
A Sobrero ◽  
A Guglielmi ◽  
M Cirillo ◽  
E Recaldin ◽  
G L Frassineti ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Advanced Colorectal Cancer ◽  
Low Cost ◽  
Highly Effective

scholarly journals A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer

2020 ◽  
Vol 6 (12) ◽  
pp. eaaw6071 ◽  
Author(s):  
Qianqian Ni ◽  
Fuwu Zhang ◽  
Yijing Liu ◽  
Zhantong Wang ◽  
Guocan Yu ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Immunotherapy ◽  
Death Receptor ◽  
Therapy Response ◽  
Complete Regression ◽  
Combination Immunotherapy ◽  
Toll Like Receptor ◽  
Physical Loading ◽  
Programmed Death ◽  
Personalized Cancer

Neoantigen vaccines have been enthusiastically pursued for personalized cancer immunotherapy while vast majority of neoantigens have no or low immunogenicity. Here, a bi-adjuvant neoantigen nanovaccine (banNV) that codelivered a peptide neoantigen (Adpgk) with two adjuvants [Toll-like receptor (TLR) 7/8 agonist R848 and TLR9 agonist CpG] was developed for potent cancer immunotherapy. Specifically, banNVs were prepared by a nanotemplated synthesis of concatemer CpG, nanocondensation with cationic polypeptides, and then physical loading with hydrophobic R848 and Adpgk. The immunogenicity of the neoantigen was profoundly potentiated by efficient codelivery of neoantigen and dual synergistic adjuvants, which is accompanied by reduced acute systemic toxicity. BanNVs sensitized immune checkpoint programmed death receptor 1 (PD-1) on T cells, therefore, a combination of banNVs with aPD-1 conspicuously induced the therapy response and led to complete regression of 70% neoantigen-specific tumors without recurrence. We conclude that banNVs are promising to optimize personalized therapeutic neoantigen vaccines for cancer immunotherapy.

A highly effective and stable bispecific diabody for cancer immunotherapy: cure of xenografted tumors by bispecific diabody and T-LAK cells

2004 ◽  
Vol 53 (6) ◽  
pp. 497-509 ◽  
Author(s):  
Hiroki Hayashi ◽  
Ryutaro Asano ◽  
Kouhei Tsumoto ◽  
Yu Katayose ◽  
Masanori Suzuki ◽  
...  
Keyword(s):  
Cancer Immunotherapy ◽  
Lak Cells ◽  
Highly Effective ◽  
Bispecific Diabody

scholarly journals Dendritic cell-based cancer immunotherapy for colorectal cancer

2016 ◽  
Vol 22 (17) ◽  
pp. 4275 ◽  
Author(s):  
Mikio Kajihara ◽  
Kazuki Takakura ◽  
Tomoya Kanai ◽  
Zensho Ito ◽  
Keisuke Saito ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Dendritic Cell ◽  
Cancer Immunotherapy

scholarly journals The tumor microenvironment of colorectal cancer metastases: opportunities in cancer immunotherapy

Immunotherapy ◽  
2020 ◽  
Vol 12 (14) ◽  
pp. 1083-1100
Author(s):  
Yasmin Kamal ◽  
Stephanie L Schmit ◽  
Hildreth Robert Frost ◽  
Christopher I Amos
Keyword(s):  
Colorectal Cancer ◽  
Tumor Microenvironment ◽  
Cancer Immunotherapy ◽  
Standard Of Care ◽  
Distant Metastases ◽  
Current Understanding ◽  
Primary Tumors ◽  
Cancer Metastases ◽  
Colorectal Cancer Metastases

About a fifth of individuals with colorectal cancer (CRC) present with disease metastasis at the time of diagnosis. While the role of the tumor microenvironment (TME) in governing CRC progression is undeniable, the role of the TME in either establishing or suppressing the formation of distant metastases of CRC is less well established. Despite advances in immunotherapy, many individuals with metastatic CRC do not respond to standard-of-care therapy. Therefore, understanding the role of the TME in establishing distant metastases is essential for developing new immunological agents. Here, we summarize our current understanding of the TME of CRC metastases, describe differences between the TME of primary tumors and their distant metastases, and discuss advances in the design and combinations of immunotherapeutic agents.

Dendritic cell‐based cancer immunotherapy: Potential for treatment of colorectal cancer?

2000 ◽  
Vol 15 (7) ◽  
pp. 698-705 ◽  
Author(s):  
Wangxue Chen ◽  
Natalie Rains ◽  
David Young ◽  
Richard S Stubbs
Keyword(s):  
Colorectal Cancer ◽  
Dendritic Cell ◽  
Cancer Immunotherapy
Sign in / Sign up

Export Citation Format

Share Document